Previous research by our group and others has demonstrated that AD patients have mildly elevated levels of plasma cortisol, that approximately 40-50% of patients do not suppress cortisol secretion normally following dexamethasone administration, and that some AD patients have blunted cortisol responses to challenges with either TRH or CRF. These abnormalities are generally correlated with the extent of behavioral impairment. Numerous animal studies indicate that chronic elevation of corticosteroids may lead to neuron loss particularly in the hippocampus and that damage to the hippocampus, in turn, can lead to disinhibition of the HPA axis. We propose to determine whether any of the observed HPA axis abnormalities observed in AD patients are related to clinically significant differences in symptom progression over time, and whether HPA axis abnormalities are associated with the loss of neurotransmitter markers or cells in the hippocampus of patients who come to autopsy. During the next five years we will collect baseline HPA axis data, perform dexamethasone suppression tests, and give CRF infusions to at least 40 mild to moderately demented AD patients at baseline and yearly for at least 2 years. Changes in HPA axis measures will be correlated with changes in AD symptomatology measured by the Alzheimer's Disease Assessment Scale. In addition we will perform these same HPA axis tests on a group of at least 30 AD patients with advanced disease who are residing in extended care facilities with high autopsy rates. Autopsies will be performed on patients in either group who die during the next five years to determine loss of neurotransmitter markers and hippocampal cells.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-10
Application #
3768076
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Girdhar, Kiran; Hoffman, Gabriel E; Jiang, Yan et al. (2018) Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome. Nat Neurosci 21:1126-1136
Huang, Qian; Voloudakis, Georgios; Ren, Yimin et al. (2018) Presenilin1/?-secretase protects neurons from glucose deprivation-induced death by regulating miR-212 and PEA15. FASEB J 32:243-253
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Giambartolomei, Claudia; Zhenli Liu, Jimmy; Zhang, Wen et al. (2018) A Bayesian framework for multiple trait colocalization from summary association statistics. Bioinformatics 34:2538-2545
Hauberg, Mads E; Fullard, John F; Zhu, Lingxue et al. (2018) Differential activity of transcribed enhancers in the prefrontal cortex of 537 cases with schizophrenia and controls. Mol Psychiatry :
Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71
Agrawal, A; Chou, Y-L; Carey, C E et al. (2018) Genome-wide association study identifies a novel locus for cannabis dependence. Mol Psychiatry 23:1293-1302

Showing the most recent 10 out of 555 publications